tbuckley/cabot-search huggingface dataset:
Reply to van Gils et al.
Authors: Jie Xu, Lili Cai, Bota Cui
Journal: Endoscopy (2024)

Letter to: Comments on the use of confocal laser endomicroscopy in diagnosing protein-losing enteropathyEndoscopy 2024; 56(02): 158-158DOI: 10.1055/a-2205-3037
ESGE and its publications
Authors: Cesare Hassan, Konstantinos Triantafyllou
Journal: Endoscopy (2024)

Significant variability in the technical performance of gastrointestinal (GI) endoscopy, overuse of endoscopy for surveillance, an underuse of more advanced endoscopic interventions, such as endoscopic submucosal dissection or endoscopic ultrasound-guided biliary drainage, are only a few of the challenges that the European Society of Gastrointestinal Endoscopy (ESGE) has sought to address through society publications. Over the past decade, ESGE has developed a rigorous, evidence-based, and reproducible standard for ESGE publications. ESGE is an amalgam of 41 national gastroenterology/endoscopy member societies; thus, ESGE publications must be of sufficiently high quality to be either directly accepted as the equivalent to the local standards of our member societies or to influence the local standard of care and thereby standardize practice within our large and diverse ESGE community.
Endoscopy International Open – recently published
Journal: Endoscopy (2024)

Comment on: Preferred techniques for endoscopic ultrasound-guided gastroenterostomy: a survey of expert endosonographersEndosc Int Open 2023; 11(11): E1035-E1045DOI: 10.1055/a-2185-6426 Comment on: Duodenal neuroendocrine tumors: Short-term outcomes of endoscopic submucosal dissection performed in the Western settingEndosc Int Open 2023; 11(11): E1099-E1107DOI: 10.1055/a-2181-0320 Comment on: Pilot study of an endoluminal-suturing device as a treatment for patients with gastroesophageal reflux diseaseEndosc Int Open 2023; 11(11): E1092-E1098DOI: 10.1055/a-2185-5947
Comments on the use of confocal laser endomicroscopy in diagnosing protein-losing enteropathy
Authors: Lukas Michaja Balsiger, Jan Tack, Magnus Simrén, Tom van Gils
Journal: Endoscopy (2024)

Letter to: Confocal laser endomicroscopy tears up the mask of protein-losing enteropathyEndoscopy 2023; 55(S 01): E1043-E1044DOI: 10.1055/a-2155-8235
A Real-World Prospective Study of the Effectiveness and Safety of Automated Insulin Delivery Compared With Other Modalities of Type 1 Diabetes Treatment During Ramadan Intermittent Fasting
Authors: Mohammed E. Al-Sofiani, Sahar Alharthi, Sarah Albunyan, Naweed Alzaman, David C. Klonoff, Abdullah Alguwaihes
Journal: Diabetes Care (2024)

OBJECTIVE To compare the fasting experience and glycemic control during Ramadan among people with type 1 diabetes (PWT1D) who use automated insulin delivery (AID) versus other modalities of treatment. RESEARCH DESIGN AND METHODS A total of 294 PWT1D who attempted fasting during Ramadan in 2022 were categorized on the basis of treatment modality into one of five groups: 1) AID (n = 62); 2) conventional pump + continuous glucose monitoring (CGM; n = 37); 3) pump + self-monitoring of blood glucose (SMBG; n = 8); 4) multiple daily injections (MDI) + CGM (n = 155); and 5) MDI + SMBG (n = 32). Predictors of fasting most days of Ramadan (i.e., breaking fast ≤2 days because of diabetes) were analyzed using uni- and multivariable logistic regression. RESULTS The median numbers of days when fasting was broken because of diabetes were 2, 5, 3, 3.5, and 2.5 for AID, conventional pump + CGM, MDI + CGM, pump + SMBG, and MDI + SMBG users, respectively (P = 0.047). Users of AID had a significantly greater time in range (TIR) and lower glycemia risk index, time below range, and time above range compared with users of conventional pumps and MDI (both P &amp;lt; 0.05). Likewise, 53% of AID users attained the double target of 1) breaking fast ≤2 days because of diabetes and 2) maintaining TIR ≥70% during Ramadan compared with only 3% of the conventional pump users and 44% of the MDI + CGM users (both P &amp;lt; 0.05). Compared with MDI + CGM users, AID users were twice as likely to complete fasting most days of Ramadan. CONCLUSIONS Use of AID is associated with the highest rates of fasting and best glycemic control during Ramadan fasting.
TREM2 function in glioblastoma immune microenvironment: Can we distinguish reality from illusion?
Authors: Sourav Ghosh, Carla V Rothlin
Journal: Neuro-Oncology (2024)

Journal Article Corrected proof TREM2 function in glioblastoma immune microenvironment: Can we distinguish reality from illusion? Get access Sourav Ghosh, Sourav Ghosh Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA Corresponding Author: Sourav Ghosh, PhD, Department of Neurology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA (sourav.ghosh@yale.edu). https://orcid.org/0000-0001-5990-8708 Search for other works by this author on: Oxford Academic PubMed Google Scholar Carla V Rothlin Carla V Rothlin Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, noae019, https://doi.org/10.1093/neuonc/noae019 Published: 30 January 2024 Article history Published: 30 January 2024 Corrected and typeset: 02 March 2024
Endoscopy E-Videos – recently published
Journal: Endoscopy (2024)

Comment on: Endoscopic retrograde appendicitis therapy for giant periappendiceal abscess with intestinal obstructionEndoscopy 2023; 55(S 01): E1116-E1117DOI: 10.1055/a-2173-7756 Comment on: Colostomy using a percutaneous lumen-apposing metal stentEndoscopy 2023; 55(S 01): E1131-E1131DOI: 10.1055/a-2173-7520 Comment on: Endoscopic intermuscular dissection of a residual rectal neuroendocrine tumor with high-pressure injection and double-clip tractionEndoscopy 2023; 55(S 01): E1126-E1127DOI: 10.1055/a-2173-7103 Comment on: Endoscopic management of complex colorectal anastomotic leakage with a pelvic collection and rectovaginal fistulaEndoscopy 2023; 55(S 01): E1135-E1136DOI: 10.1055/a-2178-4008
Repurposing iron chelators for accurate positron emission tomography imaging tracking of radiometal‐labeled cell transplants
Authors: Qian Xu, Xinyu Wang, Ziqian Mu, Yixiang Zhou, Xiang Ding, Xin Ji, Junjie Yan, Donghui Pan, Chongyang Chen, Yuping Xu, Lizhen Wang, Jing Wang, Guangji Wang, Min Yang
Journal: MedComm (2024)

Abstract The use of radiolabeled cells for positron emission tomography (PET) imaging tracking has been a promising approach for monitoring cell‐based therapies. However, the presence of free radionuclides released from dead cells during tracking can interfere with the signal from living cells, leading to inaccurate results. In this study, the effectiveness of the iron chelators deferoxamine (DFO) and deferiprone in removing free radionuclides 89 Zr and 68 Ga, respectively, was demonstrated in vivo utilizing PET imaging. The use of DFO during PET imaging tracking of 89 Zr‐labeled mesenchymal stem cells (MSCs) significantly reduced uptake in bone while preserving uptake in major organs, resulting in more accurate and reliable tracking. Furthermore, the clearance of free 89 Zr in vivo resulted in a significant reduction in radiation dose from 89 Zr‐labeled MSCs. Additionally, the avoidance of free radionuclide accumulation in bone allowed for more precise observation of the homing process and persistence during bone marrow transplantation. The efficacy and safety of this solution suggest this finding has potential for widespread use in imaging tracking studies involving various cells. Moreover, since this method employed iron chelator drugs in clinical use, which makes it is a good prospect for clinical translation.
Oncolytic Peptide‐Nanoplatform Drives Oncoimmune Response and Reverses Adenosine‐Induced Immunosuppressive Tumor Microenvironment
Authors: Ye Wu, Jia‐Yi Lin, Yu‐Dong Zhou, Hai‐Jun Liu, Sheng‐Xin Lu, Xiao‐Kun Zhang, Ying‐Yun Guan, Dale G. Nagle, Wei‐Dong Zhang, Hong‐Zhuan Chen, Xin Luan
Journal: Advanced Healthcare Materials (2024)

The application of oncolytic peptides has become a powerful approach to induce complete and long-lasting remission in multiple types of carcinomas, as affirmed by the appearance of tumor-associated antigens and adenosine triphosphate (ATP) in large quantities, which jumpstarts the cancer-immunity cycle. However, the ATP breakdown product adenosine is a significant contributor to forming the immunosuppressive tumor microenvironment, which substantially weakens peptide-driven oncolytic immunotherapy. In this study, a lipid-coated micelle (CA@TLM) loaded with a stapled oncolytic peptide (PalAno) and an adenosine 2A receptor (A2AR) inhibitor (CPI-444) is devised to enact tumor-targeted oncolytic immunotherapy and to overcome adenosine-mediated immune suppression simultaneously. The CA@TLM micelle accumulates in tumors with high efficiency, and the acidic tumor microenvironment prompts the rapid release of PalAno and CPI-444. Subsequently, PalAno induces swift membrane lysis of tumor cells and the release of antigenic materials. Meanwhile, CPI-444 blocks the activation of the immunosuppressive adenosine-A2AR signaling pathway. This combined approach exhibits pronounced synergy at stalling tumor growth and metastasis in animal models for triple-negative breast cancer and melanoma, providing a novel strategy for enhanced oncolytic immunotherapy.
Targeted therapy done right: Direct sonic hedgehog inhibition for sonic hedgehog medulloblastoma
Authors: Anandani Nellan, Sadhana Jackson
Journal: Neuro-Oncology (2024)

Journal Article Targeted therapy done right: Direct sonic hedgehog inhibition for sonic hedgehog medulloblastoma Get access Anandani Nellan, Anandani Nellan Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USASurgical Neurology Branch, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Sadhana Jackson Sadhana Jackson Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA Corresponding Author: Sadhana Jackson, MD, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, 7D45, Bethesda, MD 20814, USA (Sadhana.jackson@nih.gov). https://orcid.org/0000-0001-6700-5621 Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, Volume 26, Issue 4, April 2024, Pages 623–624, https://doi.org/10.1093/neuonc/noae018 Published: 30 January 2024 Article history Published: 30 January 2024 Corrected and typeset: 28 February 2024
Therapeutic endoscopy and appendiceal lesions – train and evaluate before intervening
Authors: Hu Bowen, Huanfei Ding
Journal: Endoscopy (2024)

Letter to: Underwater cap-suction pseudopolyp formation for endoscopic mucosal resection: a simple technique for treating flat, appendiceal orifice or ileocecal valve colorectal lesionsEndoscopy 2023; 55(11): 1045-1050DOI: 10.1055/a-2115-7797
Unveiling the hidden threat: esophageal squamous cell neoplasm in patients with head and neck squamous cell carcinoma
Authors: Xiaohan Jiang, Min Wang, Min Fu, Zhining Fan
Journal: Endoscopy (2024)

Letter to: Endoscopic screening of the upper gastrointestinal tract for second primary tumors in patients with head and neck cancer in a Western countryEndoscopy 2023; 55(11): 981-990DOI: 10.1055/a-2111-5935
Conformational activation and inhibition of von Willebrand factor by targeting its autoinhibitory module
Authors: Nicholas A. Arce, Zoe Markham-Lee, Qian Liang, Shabir Najmudin, Emily R. Legan, Gabrielle Dean, Ally J. Su, Moriah S. Wilson, Robert F. Sidonio, Pete Lollar, Jonas Emsley, Renhao Li
Journal: Blood (2024)
Fetal and Early-Life Stove and Fuel Interventions and Respiratory Oscillometry Lung Function Measures in Preschool-Aged Children from Ghana
Authors: Eric D. McCollum, William Checkley, Kalpana Balakrishnan, Thomas F. Clasen, Jennifer L. Peel
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

"Fetal and Early Life Stove and Fuel Interventions and Respiratory Oscillometry Lung Function Measures in Pre-School Aged Children from Ghana." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Bioactive nanomaterials kickstart early repair processes and potentiate temporally modulated healing of healthy and diabetic wounds
Authors: Deepanjan Ghosh, Jordan R. Yaron, Muhammad Raisul Abedin, Sudhakar Godeshala, Suneel Kumar, Jacquelyn Kilbourne, Francois Berthiaume, Kaushal Rege
Journal: Biomaterials (2024)
Design and implementation of a humanitarian cancer care programme for Ukrainian refugees in Moldova and Romania
Authors: Horia Vulpe, Artiom Minzatean, Irena Tocino, Ruslan Baltaga, Gabriel Kacso, Claudia Oprea, Veronica Ciobanu, Sergiu Brenister, Ciprian Tomuleasa, Gabriel Ricu, Rodica Mindruta-Stratan, Catalin Danaila, Dragos Iancu, Ludmila Circiumari, Cristian Teglas, Lars Lonnback, Violina Nazaria, Ursula Wagner, Eugenia Ciubotaru, Nicoleta Minzatean, Ciprian Jitaru, Stanislav Polozov, Inessa Matiushenko, Anna Uzlova, Richard Sullivan, Stefania Magidson
Journal: The Lancet Oncology (2024)
Guidelines of care for the management of acne vulgaris
Authors: Rachel V. Reynolds, Howa Yeung, Carol E. Cheng, Fran Cook-Bolden, Seemal R. Desai, Kelly M. Druby, Esther E. Freeman, Jonette E. Keri, Linda F. Stein Gold, Jerry K.L. Tan, Megha M. Tollefson, Jonathan S. Weiss, Peggy A. Wu, Andrea L. Zaenglein, Jung Min Han, John S. Barbieri
Journal: Journal of the American Academy of Dermatology (2024)
mTORC1 controls murine postprandial hepatic glycogen synthesis via Ppp1r3b
Authors: Kahealani Uehara, Won Dong Lee, Megan Stefkovich, Dipsikha Biswas, Dominic Santoleri, Anna Garcia Whitlock, William Quinn, Talia Coopersmith, Kate Townsend Creasy, Daniel J. Rader, Kei Sakamoto, Joshua D. Rabinowitz, Paul M. Titchenell
Journal: Journal of Clinical Investigation (2024)

In response to a meal, insulin drives hepatic glycogen synthesis to help regulate systemic glucose homeostasis. The mechanistic target of rapamycin complex 1 (mTORC1) is a well-established insulin target and contributes to the postprandial control of liver lipid metabolism, autophagy, and protein synthesis. However, its role in hepatic glucose metabolism is less understood. Here, we used metabolomics, isotope tracing, and mouse genetics to define a role for liver mTORC1 signaling in the control of postprandial glycolytic intermediates and glycogen deposition. We show that mTORC1 is required for glycogen synthase activity and glycogenesis. Mechanistically, hepatic mTORC1 activity promotes the feeding-dependent induction of Ppp1r3b, a gene encoding a phosphatase important for glycogen synthase activity whose polymorphisms are linked to human diabetes. Re-expression of Ppp1r3b in livers lacking mTORC1 signaling enhances glycogen synthase activity and restores postprandial glycogen content. mTORC1-dependent transcriptional control of Ppp1r3b is facilitated by FOXO1, a well characterized transcriptional regulator involved in the hepatic response to nutrient intake. Collectively, we identify a role for mTORC1 signaling in the transcriptional regulation of Ppp1r3b and the subsequent induction of postprandial hepatic glycogen synthesis.
Adrenoceptor Desensitization: Current Understanding of Mechanisms
Authors: Dina Maaliki, Aneese A. Jaffa, Suzanne Nasser, Amirhossein Sahebkar, Ali H. Eid, Paul Insel
Journal: Pharmacological Reviews (2024)

G-protein coupled receptors (GPCRs) transduce a wide range of extracellular signals. They are key players in the majority of biological functions including vision, olfaction, chemotaxis and immunity. However, as essential as most of them are to body function and homeostasis, overactivation of GPCRs has been implicated in many pathological diseases such as cancer, asthma and heart failure (HF). Therefore, an important feature of G protein signaling systems is the ability to control GPCR responsiveness, and one key process to control overstimulation involves initiating receptor desensitization. A number of steps are appreciated in the desensitization process, including cell surface receptor phosphorylation, internalization and down-regulation. Rapid or short-term desensitization occurs within minutes and involves receptor phosphorylation via the action of intracellular protein kinases, the binding of β-arrestins and the consequent uncoupling of GPCRs from their cognate heterotrimeric G proteins. On the other hand, long-term desensitization occurs over hours to days, and involves receptor downregulation or a decrease in cell surface receptor protein level. Of the proteins involved in this biological phenomenon, β-arrestins play a particularly significant role in both short- and long-term desensitization mechanisms. In addition, β-arrestins are involved in the phenomenon of biased agonism, where the biased ligand preferentially activates one of several downstream signaling pathways, leading to altered cellular responses. In this context, this review discusses the different patterns of desensitization of the <i>α</i><sub>1</sub>-, <i>α</i><sub>2</sub>- and the β adrenoceptors and highlights the role of β-arrestins in regulating physiological responsiveness through desensitization and biased agonism. <b>Significance Statement</b> A sophisticated network of proteins orchestrates the molecular regulation of G protein coupled receptor (GPCR) activity. Adrenoceptors are GPCRs that play vast roles in many physiological processes. Without tightly-controlled desensitization of these receptors, homeostatic imbalance may ensue, thus precipitating various diseases. Here, we critically appraise the mechanisms implicated in adrenoceptor desensitization. A better understanding of these mechanisms helps identify new druggable targets within the GPCR desensitization machinery and opens exciting therapeutic fronts in the treatment of several pathologies.
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Authors: Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros
Journal: Pharmacological Reviews (2024)

Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype. Consequently, the metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) therapeutic pipeline is expanding rapidly and in multiple directions. In parallel, non-invasive tools for diagnosing and monitoring responses to therapeutic interventions are being studied, and clinically feasible findings are being explored as primary outcomes in interventional trials. The realization that distinct subgroups exist under the umbrella of SLD should guide more precise and personalized treatment recommendations and facilitate advancements in pharmacotherapeutics. This review summarizes recent updates of pathophysiology-based nomenclature and outlines both effective pharmacotherapeutics and those in the pipeline for MASLD/MASH, detailing their mode of action and the current status of phase 2 and 3 clinical trials. Of the extensive arsenal of pharmacotherapeutics in the MASLD/MASH pipeline, several have been rejected, whereas other, mainly monotherapy options, have shown only marginal benefits and are now being tested as part of combination therapies, yet others are still in development as monotherapies. Although the successful drug candidate (or combinations) remains elusive, such therapeutic approaches will ideally target MASH and fibrosis while improving cardiometabolic risk factors. Due to the urgent need for the development of novel therapeutic strategies and the potential availability of safety and tolerability data, repurposing of existing and approved drugs is an appealing option. Finally, it is essential to highlight that SLD and, by extension, MASLD should be recognized and approached as a systemic disease affecting multiple organs, with the vigorous implementation of interdisciplinary and coordinated action plans. <b>Significance Statement</b> SLD, including, among others, MASLD and MASH, is considered the most prevalent chronic liver condition affecting more than one-fourth of the global population. This review aims to provide the most recent information regarding SLD pathophysiology, diagnosis, and management options, in line with the most current advancements in the guidelines and clinical trials. Collectively, it is hoped that the information provided furthers the understanding of the current state of SLD with direct clinical implications and stimulates additional research initiatives.
The Role of G Protein–Coupled Receptors and Receptor Kinases in Pancreatic<i>β</i>-Cell Function and Diabetes
Authors: Matthew J. Varney, Jeffrey L. Benovic
Journal: Pharmacological Reviews (2024)

Type 2 diabetes mellitus (T2D) has emerged as a major global health concern that has accelerated in recent years due to poor diet and lifestyle. Afflicted individuals have high blood glucose levels that stem from the inability of the pancreas to make enough insulin to meet demand. While medication can help to maintain normal blood glucose levels in individuals with chronic disease, many of these medicines are outdated, have severe side effects, and often become less efficacious over time necessitating the need for insulin therapy. G protein-coupled receptors (GPCRs) regulate many physiological processes including blood glucose levels. In pancreatic β-cells, GPCRs regulate β-cell growth, apoptosis, and insulin secretion which are all critical in maintaining sufficient β-cell mass and insulin output to ensure euglycemia. In recent years, new insight into the signaling of incretin receptors and other GPCRs have underscored the potential of these receptors as desirable targets in the treatment of diabetes. The signaling of these receptors is modulated by GPCR kinases (GRKs) that phosphorylate agonist activated GPCRs marking the receptor for arrestin binding and internalization. Interestingly, genome wide association studies (GWAS) using diabetic patient cohorts link the GRKs and arrestins with T2D. Moreover, recent reports show that GRKs and arrestins expressed in the β-cell serve a critical role in the regulation of β-cell function including β-cell growth and insulin secretion in both GPCR dependent and independent pathways. In this review, we describe recent insight into GPCR signaling and the importance of GRK function in modulating β-cell physiology. <b>Significance Statement</b> Pancreatic β-cells contain a diverse array of GPCRs that have been shown to improve β-cell function and survival, yet only a handful have been successfully targeted in the treatment of diabetes. This review discusses recent advances in our understanding of β-cell GPCR pharmacology and regulation by GRKs while also highlighting the necessity of investigating islet enriched GPCRs that have largely been unexplored to unveil novel treatment strategies.